The Pathogenesis of Nonalcoholic Fatty Liver Disease: Interplay between Diet, Gut Microbiota, and Genetic Background

Gastroenterology Research and Practice

Volumn 2016, Issue , 2016, Pages

  Yu, Jinsheng ^a   Marsh, Sharon ^b   Hu, Junbo ^c   Feng, Wenke ^d   Wu, Chaodong ^e  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d University of Louisville School of Medicine   (United States)

^e Div Gastroenterol Univ Texas M   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; FRUCTOSE; SATURATED FATTY ACID; VERY LOW DENSITY LIPOPROTEIN;

ADIPOSE TISSUE; DIET; DIET SUPPLEMENTATION; DISEASE COURSE; ENDOPLASMIC RETICULUM STRESS; ENDOTOXEMIA; GENE; GENETIC BACKGROUND; GENETIC VARIABILITY; HUMAN; INSULIN RESISTANCE; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; LIPID PEROXIDATION; LIPOGENESIS; LIPOTOXICITY; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PNPLA3 GENE; REVIEW; TM6SF2 GENE;

EID: 84973121726     PISSN: 16876121     EISSN: 1687630X     Source Type: Journal    
DOI: 10.1155/2016/2862173     Document Type: Review

References (145)

1. M. Demir, S. Lang, and H. Steffen, "Nonalcoholic fatty liver disease: current status and future directions," Journal of Digestive Diseases, vol. 16, no. 10, pp. 541-557, 2015.
2. D. G. Tiniakos,M. B. Vos, and E. M. Brunt, "Nonalcoholic fatty liver disease: pathology and pathogenesis," Annual Review of Pathology: Mechanisms of Disease, vol. 5, pp. 145-171, 2010.
3. A. Abu-Shanab and E. M. M. Quigley, "The role of the gut microbiota in nonalcoholic fatty liver disease," Nature Reviews Gastroenterology and Hepatology, vol. 7, no. 12, pp. 691-701,2010.
4. P. Angulo, "Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance?" Hepatology, vol. 51, no. 2, pp. 373-375, 2010.
5. C. Soderberg, P. Stal, J. Askling et al., "Decreased survival of subjects with elevated liver function tests during a 28-year follow-up," Hepatology, vol. 51, no. 2, pp. 595-602, 2010.
6. Y. Zhou, G. Llauradó, M. Oresic, T. Hyötyläinen, M. Orho-Melander, and H. Yki-Järvinen, "Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2," Journal of Hepatology, vol. 62, no. 3, pp. 657-663, 2015.
7. R. Lomonaco, C. Ortiz-Lopez, B. Orsak et al., "Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease," Hepatology, vol. 55, no. 5, pp. 1389-1397, 2012.
8. G. Pagano, G. Pacini, G. Musso et al., "Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association," Hepatology, vol. 35, no. 2, pp. 367-372, 2002.
9. A. J. Sanyal, C. Campbell-Sargent, F. Mirshahi et al., "Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities," Gastroenterology, vol. 120, no. 5, pp. 1183-1192, 2001.
10. M.-E. Dumas, J. Kinross, and J. K. Nicholson, "Metabolic phenotyping and systems biology approaches to understanding metabolic syndrome and fatty liver disease," Gastroenterology, vol. 146, no. 1, pp. 46-62, 2014.
11. D. Schuppan and J. M. Schattenberg, "Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches," Journal of Gastroenterology and Hepatology, vol. 28, supplement 1, pp. 68-76, 2013.
12. C. P. Day and O. F. W. James, "Steatohepatitis: A tale of two 'hits'?" Gastroenterology, vol. 114, no. 4 I, pp. 842-845, 1998.
13. A. Berson, V. De Beco, P. Letteron et al., "Steatohepatitisinducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes," Gastroenterology, vol. 114, no. 4, pp. 764-774, 1998.
14. H. Tilg and A. R. Moschen, "Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis," Hepatology, vol. 52, no. 5, pp. 1836-1846, 2010.
15. A. R. Johnson, J. J. Milner, and L. Makowski, "The inflammation highway: metabolism accelerates inflammatory traffic in obesity," Immunological Reviews, vol. 249, no. 1, pp. 218-238, 2012.
16. S. C. Matherly and P. Puri, "Mechanisms of simple hepatic steatosis: not so simple after all," Clinics in Liver Disease, vol. 16, no. 3, pp. 505-524, 2012.
17. R. Barbuio, M. Milanski, M. B. Bertolo, M. J. Saad, and L. A. Velloso, "Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet," Journal of Endocrinology, vol. 194, no. 3, pp. 539-550, 2007.
18. H. Tilg, "The role of cytokines in non-alcoholic fatty liver disease," Digestive Diseases, vol. 28, no. 1, pp. 179-185, 2010.
19. C. M. Hasenour, E. D. Berglund, and D. H. Wasserman, "Emerging role ofAMP-activated protein kinase in endocrine control of metabolism in the liver," Molecular and Cellular Endocrinology, vol. 366, no. 2, pp. 152-162, 2013.
20. X. Ouyang, P. Cirillo, Y. Sautin et al., "Fructose consumption as a risk factor for non-alcoholic fatty liver disease," Journal of Hepatology, vol. 48, no. 6, pp. 993-999, 2008.
21. N. Assy, G. Nasser, I. Kamayse et al., "Soft drink consumption linked with fatty liver in the absence of traditional risk factors," Canadian Journal of Gastroenterology, vol. 22, no. 10, pp. 811-816, 2008.
22. S. Zelber-Sagi, D. Nitzan-Kaluski, R. Goldsmith et al., "Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): A population based study," Journal of Hepatology, vol. 47, no. 5, pp. 711-717, 2007.
23. M. V. Machado, P. Ravasco, L. Jesus et al., "Blood oxidative stress markers in non-alcoholic steatohepatitis and how it correlates with diet," Scandinavian Journal of Gastroenterology, vol. 43, no. 1, pp. 95-102, 2008.
24. J. E. Lambert, M. A. Ramos-Roman, J. D. Browning, and E. J. Parks, "Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease," Gastroenterology, vol. 146, no. 3, pp. 726-735, 2014.
25. L. C. Hudgins, T. S. Parker, D. M. Levine, and M. K. Hellerstein, "A dual sugar challenge test for lipogenic sensitivity to dietary fructose," Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 3, pp. 861-868, 2011.
26. V. Lecoultre, L. Egli, G. Carrel et al., "Effects of fructose and glucose overfeeding on hepatic insulin sensitivity and intrahepatic lipids in healthy humans," Obesity, vol. 21, no. 4, pp. 782-785, 2013.
27. E. J. Parks, L. E. Skokan, M. T. Timlin, and C. S. Dingfelder, "Dietary sugars stimulate fatty acid synthesis in adults," Journal of Nutrition, vol. 138, no. 6, pp. 1039-1046, 2008.
28. K. L. Stanhope, J. M. Schwarz, N. L. Keim et al., "Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans,"The Journal of Clinical Investigation, vol. 119, no. 5, pp. 1322-1334, 2009.
29. M. F. Abdelmalek, A. Suzuki, C. Guy et al., "Increased fructose consumption is associatedwith fibrosis severity in patientswith nonalcoholic fatty liver disease," Hepatology, vol. 51, no. 6, pp. 1961-1971, 2010.
30. J. Lin, R. Yang, P. T. Tarr et al., "Hyperlipidemic effects of dietary saturated fatsmediated through PGC-1 coactivation of SREBP," Cell, vol. 120, no. 2, pp. 261-273, 2005.
31. R. M. Mancina, N. Matikainen, C. Maglio et al., "Paradoxical dissociation between hepatic fat content and de novo lipogenesis due to PNPLA3 sequence variant," Journal of Clinical Endocrinology and Metabolism, vol. 100, no. 5, pp. E821-E825, 2015.
32. H. Tilg and A. R. Moschen, "Inflammatory mechanisms in the regulation of insulin resistance,"MolecularMedicine, vol. 14, no. 3-4, pp. 222-231, 2008.
33. A. Gastaldelli, K. Cusi, M. Pettiti et al., "Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects,"Gastroenterology, vol. 133, no. 2,pp. 496-506, 2007.
34. K. Sevastianova, A. Kotronen, A. Gastaldelli et al., "Genetic variation in PNPLA3 (adiponutrin) confers sensitivity toweight loss-induced decrease in liver fat in humans," The American Journal of Clinical Nutrition, vol. 94, no. 1, pp. 104-111, 2011.
35. K. Kantartzis,A. Peter, F. Machicao et al., "Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene," Diabetes, vol. 58, no. 11, pp. 2616-2623, 2009.
36. J. Kozlitina, E. Smagris, S. Stender et al., "Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease," Nature Genetics, vol. 46, no. 4, pp. 352-356, 2014.
37. K. Kantartzis, F. Machicao, J. Machann et al., "The DGAT2 gene is a candidate for the dissociation between fatty liver and insulin resistance in humans," Clinical Science, vol. 116, no. 6, pp. 531-537, 2009.
38. M. E. Visser, N. M. Lammers, A. J. Nederveen et al., "Hepatic steatosis does not cause insulin resistance in people with familial hypobetalipoproteinaemia," Diabetologia, vol. 54, no. 8, pp. 2113-2121, 2011.
39. A. Amaro, E. Fabbrini, M. Kars et al., "Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia," Gastroenterology, vol. 139, no. 1, pp. 149-153, 2010.
40. C. N. A. Palmer, C. Maglio, C. Pirazzi et al., "Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant," PLoS ONE, vol. 7, no. 6,Article ID e39362, 2012.
41. M. Gaggini, M. Morelli, E. Buzzigoli, R. A. DeFronzo, E. Bugianesi, and A. Gastaldelli, "Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease," Nutrients, vol. 5, no. 5, pp. 1544-1560, 2013.
42. M. Fuchs and A. J. Sanyal, "Lipotoxicity in NASH," Journal of Hepatology, vol. 56, no. 1, pp. 291-293, 2012.
43. P. Simonen, A. Kotronen, M. Hallikainen et al., "Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity," Journal of Hepatology, vol. 54, no. 1, pp. 153-159, 2011.
44. G. Arguello, E. Balboa, M. Arrese, and S. Zanlungo, "Recent insights on the role of cholesterol in non-alcoholic fatty liver disease," Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, vol. 1852, no. 9, pp. 1765-1778, 2015.
45. H. Malhi, S. F. Bronk, N. W. Werneburg, and G. J. Gores, "Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis," The Journal of Biological Chemistry, vol. 281, no. 17, pp. 12093-12101, 2006.
46. T. Sharifnia, J. Antoun, T. G. C. Verriere et al., "Hepatic TLR4 signaling in obese NAFLD," American Journal of Physiology- Gastrointestinal and Liver Physiology, vol. 309, no. 4, pp. G270-G278, 2015.
47. G. Serviddio, F. Bellanti, R. Tamborra et al., "Alterations of hepatic ATP homeostasis and respiratory chain during development of non-alcoholic steatohepatitis in a rodent model," EuropeanJournal of Clinical Investigation, vol. 38,no. 4, pp. 245-252, 2008.
48. Y. Jiang, M. Zhao, and W. An, "Increased hepatic apoptosis in high-fat diet-induced NASH in rats may be associated with downregulation of hepatic stimulator substance," Journal of Molecular Medicine, vol. 89, no. 12, pp. 1207-1217, 2011.
49. X. Jin, Y.-D. Yang, K. Chen et al., "HDMCP uncouples yeast mitochondrial respiration and alleviates steatosis in L02 and hepG2 cells by decreasing ATP and H2O2 levels: A novel mechanism for NAFLD," Journal of Hepatology, vol. 50, no. 5, pp. 1019-1028, 2009.
50. C. P. Day, "Pathogenesis of steatohepatitis," Best Practice & Research Clinical Gastroenterology, vol. 16, no. 5, pp. 663-678, 2002.
51. H. A. Sadek, P. A. Szweda, and L. I. Szweda, "Modulation of mitochondrial complex I activity by reversible Ca2+ and NADH mediated superoxide anion dependent inhibition," Biochemistry, vol. 43, no. 26, pp. 8494-8502, 2004.
52. C. C. Kujoth, A. Hiona, T. D. Pugh et al., "Medicine: mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging," Science, vol. 309, no. 5733, pp. 481-484, 2005.
53. C. P. Day, "Non-alcoholic fatty liver disease: current concepts and management strategies," Clinical Medicine, vol. 6, no. 1, pp. 19-25, 2006.
54. G. H. Koek, P. R. Liedorp, and A. Bast, "The role of oxidative stress in non-alcoholic steatohepatitis," Clinica Chimica Acta, vol. 412, no. 15-16, pp. 1297-1305, 2011.
55. B. Nowicka and J. Kruk, "Occurrence, biosynthesis and function of isoprenoid quinones," Biochimica et Biophysica Acta (BBA)- Bioenergetics, vol. 1797, no. 9, pp. 1587-1605, 2010.
56. D. Pessayre, "Role of mitochondria in non-alcoholic fatty liver disease," Journal of Gastroenterology and Hepatology, vol. 22, supplement 1, pp. S20-S27, 2007.
57. E. Novo, C. Busletta, L. V. D. Bonzo et al., "Intracellular reactive oxygen species are required for directional migration of resident and bonemarrow-derived hepatic pro-fibrogenic cells," Journal of Hepatology, vol. 54, no. 5, pp. 964-974, 2011.
58. G. S. Hotamisligil, "Endoplasmic reticulum stress and the inflammatory basis of metabolic disease," Cell, vol. 140, no. 6, pp. 900-917, 2010.
59. U. Ozcan, Q. Cao, E. Yilmaz et al., "Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes," Science, vol. 306, no. 5695, pp. 457-461, 2004.
60. D. Ron and P. Walter, "Signal integration in the endoplasmic reticulum unfolded protein response," Nature Reviews Molecular Cell Biology, vol. 8, no. 7, pp. 519-529, 2007.
61. J. Lee and U. Ozcan, "Unfolded protein response signaling and metabolic diseases," The Journal of Biological Chemistry, vol. 289, no. 3, pp. 1203-1211, 2014.
62. C. Hetz, "The unfolded protein response: controlling cell fate decisions under ER stress and beyond," Nature Reviews Molecular Cell Biology, vol. 13, no. 2, pp. 89-102, 2012.
63. V. Zambo, L. Simon-Szabo, P. Szelenyi et al., "Lipotoxicity in the liver," World Journal of Hepatology, vol. 5, no. 10, pp. 550-557, 2013.
64. P. S. Langendijk, F. Schut, G. J. Jansen et al., "Quantitative fluorescence in situ hybridization of Bifidobacterium spp. with genus-specific 16S rRNA-targeted probes and its application in fecal samples," Applied and EnvironmentalMicrobiology, vol. 61, no. 8, pp. 3069-3075, 1995.
65. G. Musso, M. Cassader, S. Cohney et al., "Emerging liverkidney interactions in nonalcoholic fatty liver disease," Trends in Molecular Medicine, vol. 21, no. 10, pp. 645-662, 2015.
66. I. A. Kirpich, L. S. Marsano, and C. J. McClain, "Gut-liver axis, nutrition, and non-alcoholic fatty liver disease," Clinical Biochemistry, vol. 48, no. 13-14, pp. 923-930, 2015.
67. P. Lin, J. Lu, Y. Wang et al., "Naturally occurring stilbenoid TSG reverses non-alcoholic fatty liver diseases via gut-liver axis," PLoS ONE, vol. 10, no. 10, Article ID e0140346, 2015.
68. P. J. Turnbaugh, R. E. Ley, M. A. Mahowald, V. Magrini, E. R. Mardis, and J. I. Gordon, "An obesity-associated gut microbiomewith increased capacity for energy harvest," Nature, vol. 444, no. 7122, pp. 1027-1031, 2006.
69. A. Schwiertz, D. Taras, K. Schäfer et al., "Microbiota and SCFA in lean and overweight healthy subjects," Obesity, vol. 18, no. 1, pp. 190-195, 2010.
70. R. E. Ley, F. Bäckhed, P. Turnbaugh, C. A. Lozupone, R. D. Knight, and J. I. Gordon, "Obesity alters gut microbial ecology," Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 31, pp. 11070-11075, 2005.
71. R. E. Ley, P. J. Turnbaugh, S. Klein, and J. I. Gordon, "Microbial ecology: human gut microbes associated with obesity," Nature, vol. 444, no. 7122, pp. 1022-1023, 2006.
72. G. den Besten, K. van Eunen, A. K. Groen, K. Venema, D.-J. Reijngoud, and B. M. Bakker, "The role of short-chainfatty acids in the interplay between diet, gut microbiota, and host energy metabolism," Journal of Lipid Research, vol. 54, no. 9, pp. 2325-2340, 2013.
73. G. den Besten, A. Bleeker, A. Gerding et al., "Short-chain fatty acids protect against high-fat diet-induced obesity via a PPAR-dependent switch from lipogenesis to fat oxidation," Diabetes, vol. 64, no. 7, pp. 2398-2408, 2015.
74. A. L. Buchman, M. D. Dubin, A. A. Moukarzel et al., "Choline deficiency: A cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation," Hepatology, vol. 22, no. 5, pp. 1399-1403, 1995.
75. M.-E. Dumas, R. H. Barton, A. Toye et al., "Metabolic profiling reveals a contribution of gutmicrobiota to fatty liver phenotype in insulin-resistant mice," Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 33, pp. 12511-12516, 2006.
76. M. D. Spencer, T. J. Hamp, R. W. Reid, L. M. Fischer, S. H. Zeisel, and A. A. Fodor, "Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency," Gastroenterology, vol. 140, no. 3, pp. 976-986, 2011.
77. D. W. Russell, "The enzymes, regulation, and genetics of bile acid synthesis," Annual Review of Biochemistry, vol. 72, pp. 137-174, 2003.
78. J. M. Ridlon, D.-J. Kang, and P. B. Hylemon, "Bile salt biotransformations by human intestinal bacteria," Journal of Lipid Research, vol. 47, no. 2, pp. 241-259, 2006.
79. S. I. Sayin, A. Wahlström, J. Felin et al., "Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-betamuricholic acid, a naturally occurring FXR antagonist," Cell Metabolism, vol. 17, no. 2, pp. 225-235, 2013.
80. F. G. Schaap, M. Trauner, and P. L. M. Jansen, "Bile acid receptors as targets for drug development," Nature Reviews Gastroenterology and Hepatology, vol. 11, no. 1, pp. 55-67, 2014.
81. Y. Li, K. Jadhav, and Y. Zhang, "Bile acid receptors in nonalcoholic fatty liver disease," Biochemical Pharmacology, vol. 86, no. 11, pp. 1517-1524, 2013.
82. T. Inagaki, M. Choi, A. Moschetta et al., "Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis," Cell Metabolism, vol. 2, no. 4, pp. 217-225, 2005.
83. R. H. McMahan, X. X. Wang, L. L. Cheng et al., "Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease," The Journal of Biological Chemistry, vol. 288, no. 17, pp. 11761-11770, 2013.
84. K. Cope, T. Risby, and A. M. Diehl, "Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis," Gastroenterology, vol. 119, no. 5, pp. 1340-1347, 2000.
85. S. Nair, K. Cope, R. H. Terence, and A. M. Diehl, "Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis," American Journal of Gastroenterology, vol. 96, no. 4, pp. 1200-1204, 2001.
86. L. Zhu, S. S. Baker, C. Gill et al., "Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH," Hepatology, vol. 57, no. 2, pp. 601-609, 2013.
87. S. S. Baker, R. D. Baker,W. Liu, N. J. Nowak, and L. Zhu, "Role of alcohol metabolism in non-alcoholic steatohepatitis," PLoS ONE, vol. 5, no. 3,Article ID e9570, 2010.
88. A. J. Engstler, T. Aumiller, C. Degen et al., "Insulin resistance alters hepatic ethanol metabolism: studies in mice and children with non-alcoholic fatty liver disease," Gut, 2015.
89. I. C. de Medeiros and J. G. de Lima, "Is nonalcoholic fatty liver disease an endogenous alcoholic fatty liver disease?-a mechanistic hypothesis," Medical Hypotheses, vol. 85, no. 2, pp. 148-152, 2015.
90. D. Artis, "Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut," Nature Reviews Immunology, vol. 8, no. 6, pp. 411-420, 2008.
91. S. Q. Yang, H. Z. Lin,M. D. Lane, M. Clemens, and A. M. Diehl, "Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis," Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 6, pp. 2557-2562, 1997.
92. P. Brun, I. Castagliuolo, V. Di Leo et al., "Increased intestinal permeability in obese mice: newevidence in the pathogenesis of nonalcoholic steatohepatitis," American Journal of Physiology- Gastrointestinal and Liver Physiology, vol. 292, no. 2, pp. G518-G525, 2007.
93. L. Miele, V. Valenza, G. La Torre et al., "Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease," Hepatology, vol. 49, no. 6, pp. 1877-1887, 2009.
94. F. Laugerette, C. Vors, A. Gélöen et al., "Emulsified lipids increase endotoxemia: possible role in early postprandial lowgrade inflammation," Journal of Nutritional Biochemistry, vol. 22, no. 1, pp. 53-59, 2011.
95. J. Yuan, S. S. Baker, W. Liu et al., "Endotoxemia unrequired in the pathogenesis of pediatric nonalcoholic steatohepatitis," Journal of Gastroenterology and Hepatology, vol. 29, no. 6, pp. 1292-1298, 2014.
96. R. Medzhitov, "Toll-like receptors and innate immunity," Nature Reviews Immunology, vol. 1, no. 2, pp. 135-145, 2001.
97. D. M. L. Tsukumo, M. A. Carvalho-Filho, J. B. C. Carvalheira et al., "Loss-of-function mutation in toll-like receptor 4 prevents diet-induced obesity and insulin resistance," Diabetes, vol. 56, no. 8, pp. 1986-1998, 2007.
98. K. Miura, Y. Kodama, S. Inokuchi et al., "Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1 in mice," Gastroenterology, vol. 139, no. 1, pp. 323-334. e7, 2010.
99. M. Vijay-Kumar, J. D. Aitken, F. A. Carvalho et al., "Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5," Science, vol. 328, no. 5975, pp. 228-231, 2010.
100. M. Wlodarska, C. A. Thaiss, R. Nowarski et al., "NLRP6 inflammasome orchestrates the colonic host-microbial interface by regulating goblet cell mucus secretion," Cell, vol. 156, no. 5, pp. 1045-1059, 2014.
101. J. Henao-Mejia, E. Elinav, C. Jin et al., "Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity," Nature, vol. 482, no. 7384, pp. 179-185, 2012.
102. A. K. Leamy, R. A. Egnatchik, and J. D. Young, "Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease," Progress in Lipid Research, vol. 52, no. 1, pp. 165-174, 2013.
103. N. deWit,M. Derrien,H. Bosch-Vermeulen et al., "Saturated fat stimulates obesity and hepatic steatosis and affects gut microbiota composition by an enhanced overflow of dietary fat to the distal intestine," American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 303, no. 5, pp. G589-G599, 2012.
104. M. J. J. Ronis, S. Korourian, M. Zipperman, R. Hakkak, and T. M. Badger, "Dietary saturated fat reduces alcoholic hepatotoxicity in rats by altering fatty acid metabolism and membrane composition," Journal of Nutrition, vol. 134, no. 4, pp. 904-912, 2004.
105. A. A. Nanji, K. Jokelainen, G. L. Tipoe, A. Rahemtulla, and A. J. Dannenberg, "Dietary saturated fatty acids reverse inflammatory and fibrotic changes in rat liver despite continued ethanol administration," Journal of Pharmacology and Experimental Therapeutics, vol. 299, no. 2, pp. 638-644, 2001.
106. I. A. Kirpich, W. Feng, Y. Wang et al., "The type of dietary fat modulates intestinal tight junction integrity, gut permeability, and hepatic toll-like receptor expression in a mouse model of alcoholic liver disease," Alcoholism: Clinical and Experimental Research, vol. 36, no. 5, pp. 835-846, 2012.
107. Y. Wei, D. Wang, F. Topczewski, and M. J. Pagliassotti, "Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells," American Journal of Physiology-Endocrinology and Metabolism, vol. 291, no. 2, pp. E275-E281, 2006.
108. D. Wang, Y. Wei, and M. J. Pagliassotti, "Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis," Endocrinology, vol. 147, no. 2, pp. 943-951, 2006.
109. G. Solinas, W. Naugler, F. Galimi, M.-S. Lee, and M. Karin, "Saturated fatty acids inhibit induction of insulin gene transcription by JNK-mediated phosphorylation of insulin-receptor substrates," Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 44, pp. 16454-16459, 2006.
110. P. Chen,M. Torralba, J. Tan et al., "Supplementationof saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice," Gastroenterology, vol. 148, no. 1, pp. 203-214. e16, 2015.
111. J. B. Moore, P. J. Gunn, and B. A. Fielding, "The role of dietary sugars and de novo lipogenesis in non-alcoholic fatty liver disease," Nutrients, vol. 6, no. 12, pp. 5679-5703, 2014.
112. T. A. O'Sullivan, W. H. Oddy, A. P. Bremner et al., "Lower fructose intake may help protect against development of nonalcoholic fatty liver in adolescents with obesity," Journal of Pediatric Gastroenterology and Nutrition, vol. 58, no. 5, pp. 624-631, 2014.
113. D. R. Mager, C. Patterson, S. So, C. D. Rogenstein, L. J. Wykes, and E. A. Roberts, "Dietary and physical activity patterns in children with fatty liver," European Journal of Clinical Nutrition, vol. 64, no. 6, pp. 628-635, 2010.
114. P. Jegatheesan, S. Beutheu, G. Ventura et al., "Effect of specific amino acids on hepatic lipid metabolism in fructose-induced non-alcoholic fatty liver disease," Clinical Nutrition, vol. 35, no. 1, pp. 175-182, 2016.
115. R. Jin, A. Willment, S. S. Patel et al., "Fructose induced endotoxemia in pediatric nonalcoholic fatty liver disease," International Journal of Hepatology, vol. 2014, Article ID 560620, 8 pages, 2014.
116. Y. Ritze, G. Bárdos, A. Claus et al., "Lactobacillus rhamnosus GG Protects against non-alcoholic fatty liver disease in mice," PLoS ONE, vol. 9, no. 1,Article ID e80169, 2014.
117. S. Wagnerberger,A. Spruss, G. Kanuri et al., "Lactobacillus casei Shirota protects from fructose-induced liver steatosis: A mouse model," Journal of Nutritional Biochemistry, vol. 24, no. 3, pp. 531-538, 2013.
118. F.-C. Hsieh, C.-L. Lee, C.-Y. Chai,W.-T. Chen, Y.-C. Lu, and C.-S. Wu, "Oral administration of Lactobacillus reuteriGMNL-263 improves insulin resistance and ameliorates hepatic steatosis in high fructose-fed rats," Nutrition and Metabolism, vol. 10, no. 1, article 35, 2013.
119. S. Wagnerberger, A. Spruss, G. Kanuri et al., "Toll-like receptors 1-9 are elevated in livers with fructose-induced hepatic steatosis," British Journal of Nutrition, vol. 107, no. 12, pp. 1727-1738, 2012.
120. F. S. Macaluso,M. Maida, and S. Petta, "Genetic background in nonalcoholic fatty liver disease: A comprehensive review," World Journal of Gastroenterology, vol. 21, no. 39, pp. 11088-11111, 2015.
121. R. M. Mancina, P. Dongiovanni, S. Petta et al., "The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent," Gastroenterology, vol. 150, no. 5, pp. 1219-1230, 2016.
122. Q. M. Anstee and C. P. Day, "The genetics of nonalcoholic fatty liver disease: spotlight on PNPLA3 and TM6SF2," Seminars in Liver Disease, vol. 35, no. 3, pp. 270-290, 2015.
123. P. Pingitore, C. Pirazzi, R. M. Mancina et al., "Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function," Biochimica et Biophysica Acta-Molecular and Cell Biology of Lipids, vol. 1841, no. 4, pp. 574-580, 2014.
124. S. He, C. McPhaul, J. Z. Li et al., "A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis,"The Journal of Biological Chemistry, vol. 285, no. 9, pp. 6706-6715, 2010.
125. A. Mondul, R. M. Mancina, A. Merlo et al., "PNPLA3 I148M variant influences circulating retinol in adults with nonalcoholic fatty liver disease or obesity," Journal of Nutrition, vol. 145, no. 8, pp. 1687-1691, 2015.
126. M. Kovarova, I. Konigsrainer, A. Konigsrainer et al., "The genetic variant I148M in PNPLA3 is associated with increased hepatic retinyl-palmitate storage in humans," The Journal of Clinical Endocrinology&Metabolism, vol. 100, no. 12, pp. E1568-E1574, 2015.
127. C. Pirazzi, L. Valenti, B. M. Motta et al., "PNPLA3 has retinylpalmitate lipase activity in human hepatic stellate cells," Human Molecular Genetics, vol. 23, no. 15, pp. 4077-4085, 2014.
128. S. Romeo, J. Kozlitina, C. Xing et al., "Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease," Nature Genetics, vol. 40, no. 12, pp. 1461-1465, 2008.
129. S. Sookoian and C. J. Pirola, "Meta-analysis of the influence of I148Mvariant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease," Hepatology, vol. 53,no. 6, pp. 1883-1894, 2011.
130. Q. M. Anstee and C. P. Day, "The genetics of NAFLD," Nature Reviews Gastroenterology and Hepatology, vol. 10, no. 11, pp. 645-655, 2013.
131. Y. Li, C. Xing, Z. Tian, and H.-C. Ku, "Genetic variant I148M in PNPLA3 is associated with the ultrasonography-determined steatosis degree in a Chinese population," BMC Medical Genetics, vol. 13, article 113, 2012.
132. S. S. Lee, Y.-S. Byoun, S.-H. Jeong et al., "Role of the PNPLA3 I148M polymorphism in nonalcoholic fatty liver disease and fibrosis in korea," Digestive Diseases and Sciences, vol. 59, no. 12, pp. 2967-2974, 2014.
133. T. Kawaguchi, Y. Sumida, A. Umemura et al., "Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese," PLoS ONE, vol. 7, no. 6,Article ID e38322, 2012.
134. S. Petta, E. Vanni, E. Bugianesi et al., "PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C," Alimentary Pharmacology and Therapeutics, vol. 41, no. 10, pp. 939-948, 2015.
135. M. Viganò, L. Valenti, P. Lampertico et al., "Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B," Hepatology, vol. 58, no. 4, pp. 1245-1252, 2013.
136. E. Trepo, E. Guyot, N. Ganne-Carrie et al., "PNPLA3 (rs738409 C>G) is a common risk variant associated with hepatocellular carcinoma in alcoholic cirrhosis," Hepatology, vol. 55, no. 4, pp. 1307-1308, 2012.
137. Y.-L. Liu, G. L. Patman, J. B. S. Leathart et al., "Carriage of the PNPLA3 rs738409 C>G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma," Journal of Hepatology, vol. 61, no. 1, pp. 75-81, 2014.
138. M. A. Burza, C. Pirazzi, C. Maglio et al., "PNPLA3 I148M (rs738409) genetic variant is associated with hepatocellular carcinoma in obese individuals," Digestive and Liver Disease, vol. 44, no. 12, pp. 1037-1041, 2012.
139. M. Krawczyk, C. S. Stokes, S. Romeo, and F. Lammert, "HCC and liver disease risks in homozygous PNPLA3 p. I148Mcarriers approach monogenic inheritance," Journal of Hepatology, vol. 62, no. 4, pp. 980-981, 2015.
140. M. Krawczyk, P. Portincasa, and F. Lammert, "PNPLA3-associated steatohepatitis: toward a gene-based classification of fatty liver disease," Seminars in Liver Disease, vol. 33, no. 4, pp. 369-379, 2013.
141. Y.-L. Liu, H. L. Reeves, A. D. Burt et al., "TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with nonalcoholic fatty liver disease," Nature Communications, vol. 5, article 4309, 2014.
142. P. Dongiovanni, S. Petta, C. Maglio et al., "Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis fromcardiovascular disease," Hepatology, vol. 61, no. 2, pp. 506-514, 2015.
143. G. Musso, M. Cassader, E. Paschetta, and R. Gambino, "TM6SF2 may drive postprandial lipoprotein cholesterol toxicity away from the vessel walls to the liver in NAFLD," Journal of Hepatology, vol. 64, no. 4, pp. 979-981, 2016.
144. T. Le Roy, M. Llopis, P. Lepage et al., "Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice," Gut, vol. 62, no. 12, pp. 1787-1794, 2013.
145. S. Ussar, N. W. Griffin, O. Bezy et al., "Interactions between gut microbiota, host genetics and diet modulate the predisposition to obesity and metabolic syndrome," Cell Metabolism, vol. 22, no. 3, pp. 516-530, 2015.